Skip to page content
  • Efficacy boost for dendritic cell therapies

    B73083

    Efficacy boost for dendritic cell therapies

    • Method to increase efficacy of existing DC-based cell therapies
    • Enzymatic treatment improves T-cell priming capacity up to 10-fold
    • Results in strong proliferation of tumor-killing T-cells
  • Novel tool for the early diagnosis of sepsis

    B79000

    Novel tool for the early diagnosis of sepsis

    • Diagnostic test for patients with suspected sepsis
    • Easy and broadly applicable test with low amount of blood
    • Allows much earlier diagnosis than currently possible
  • Success Prediction of an Allergen- specific Immunotherapy

    B76137

    Success Prediction of an Allergen- specific Immunotherapy

    • Innovative prediction method for the therapeutic success of an allergen-specific immunotherapy (AIT) at an early stage
    • straightforward and easy determination of the relevant parameters from nasal sample material
    • patient-friendly and economic
  • Hydrogels: Injectable Depot-Systems

    B76151

    Hydrogels: Injectable Depot-Systems

    • Gelatinize by a dual mechanism based on Diels-Alder reaction and physical crosslinking
    • Stability and stiffness can be adjusted to therapeutic need
    • Hydrogels are stable, in situ forming, non-toxic and particularly suitable for controlled drug release
  • Immunotherapy for Chronic Liver Diseases

    B72272

    Immunotherapy for Chronic Liver Diseases

    • Novel vaccination strategy against chronic liver diseases through stimulation of IMATEs with TLR9-L
    • IMATEs are an anatomic compartment within the liver tissue consisting of myeloid cells
    • iMATEs overcome regulatory cues that limit immune response during chronic liver infections
  • Amyloid Inhibitory Peptides for Alzheimer’s Disease and Diabetes

    B78094

    Amyloid Inhibitory Peptides for Alzheimer’s Disease and Diabetes

    • macrocyclic peptides (MCIPs): novel class of nanomolar amyloid inhibitors of both Aβ40(42) and IAPP or of Aβ40(42) alone
    • candidates/leads for macrocyclic peptide‐based anti‐amyloid drugs
    • scaffolds for the design of small‐molecule peptidomimetics for targeting amyloidogenesis
  • Protein Purification/Immobilization through negPeps

    B76080

    Protein Purification/Immobilization through negPeps

    • NegPeps (magnetic particle binding peptides) are novel peptides with the potential to replace the common affinity tags based protein purification/immobilization
    • NegPeps bind to magnetic nanoparticles in a reversible and controlled manner
    • No specific surface functionalization necessary
  • NF-κB-activated dendritic cells

    B71259

    NF-κB-activated dendritic cells

    • that has very little adverse effects and overcomes the limitations of DC based immunotherapy approaches
    • DCs activation is mediated by via mRNA transfection
    • Activated DCs lead to strong expansion of memory T cells and are much more stable than other DC vaccination products
  • Urinary marker for bladder cancer detection

    B71211

    Urinary marker for bladder cancer detection

    • The focal adhesion protein LASP-1 is a novel and simply detectable marker for urothelial carcinoma of the bladder (UCB)
    • LASP-1 overcomes the limitation of currently used cystoscopy and urine cytology for diagnosis of UCB
    • LASP-1 is detected in voided urine sediment of bladder cancer patients and is combinable with a second marker to further raise specificity/sensitivity
  • Needle assembly for relieving a pneumothorax

    B77122

    Needle assembly for relieving a pneumothorax

    • Fast and easy to use medical device for relieving a Pneumothorax
    • Enables safe patient transport
    • Prevents serious inadvertent injuries
  • Glyko-engineered interleukin-4 based antagonists

    B77153

    Glyko-engineered interleukin-4 based antagonists

    • New strategy for the generation of a novel IL4-based IL4/IL13-Inhibitor
    • Innovative application of N-glycan structures for development of receptor antagonists
    • Applicable for following areas: atopic dermatitis, allergy and allergic asthma
  • Improving Stability and Secretion of ­Antibodies

    B73076

    Improving Stability and Secretion of ­Antibodies

    • Improvement of the biophysical properties of antibodies and enhancement of antibody secretion by imitating the stabilizing structural elements of shark antibodies
    • CL domain is modified by a conservative exchange of amino acids at two positions
    • Compared to the wild type CL, the melting point of the modified CL domain is almost 10°C higher and its stability against urea-induced denaturation is also markedly increased
  • New Catalyst System for High ­Performance Polymers

    B75246 | B74151 | B76002 | B76107 | B76177

    New Catalyst System for High ­Performance Polymers

    • Superior method for the polymerization of Michael-type based monomers
    • New versatile catalyst system
    • Cheaper, fasterand greener process
  • A convertible multi-purpose bioreactor

    B76089

    A convertible multi-purpose bioreactor

    • Convertible multi-purpose bioreactor provides 4in1 combination of different types of bioreactosr:
    • stirred-tank bioreactor
    • gas-lift bioreactor
    • packed-bed biofilm reactor
    • trickling filter biofilm reactor
  • Mobilizing brown fat thermogenesis

    B75239

    Mobilizing brown fat thermogenesis

    • Secretin promotes energy expenditure
    • Secretin-activated brown fat promotes satiation
    • Treatment option for obese and diabetes patients
  • Cannula for ocular micro-injection

    B75028

    Cannula for ocular micro-injection

    • ‍Intra- and sub-retinal targeted administration of drugs
    • Easy and highly precise targeting
    • Treatment of Age-related Macular Degeneration (AMD)
  • A new target in cancer therapy

    B74064

    A new target in cancer therapy

    • Cancer cells use an extracellular citrate supply as an important energy source and substrate for the synthesis of critical cellular building blocks (e.g. fatty acids).
    • A highly specialized plasma membrane protein (pmCiC, plasma membrane citrate carrier) was found to be responsible for citrate uptake in cancer cells
    • pmCiC is a novel and specific marker and therapeutic target for cancer cells
  • Small molecule hdac6 inhibitors

    B73271

    Small molecule hdac6 inhibitors

    • ‍HDAC6 is a promising target for the treatment of chronic immune and inflammatory disorders such as rheumatoid arthritis (RA)
    • Marbostat are new small molecule inhibitors of HDAC6 with superior characteristics: in comparison to the established HDAC6 inhibitor Tubastatin A, the new inhibitors are more potent and specific, and most importantly they highly and selectively inhibit the enzyme activity of HDAC6 without destroying the protein.
    • Provision of a viable alternative to first line NSAIDs (non-steroidal anti-inflammatory drugs) in the treatment of RA
  • Small molecule inhibitors of CD40-TRAF6 ­interactions

    B72031

    Small molecule inhibitors of CD40-TRAF6 ­interactions

    • New selective inhibitors for treatment of chronic inflammatory diseases, such as atherosclerosis, obesity and multiple sclerosis.
    • Inhibitors selectively block CD40-TRAF6 interactions
    • The selective blockage of the CD40-TRAF6 interactions strongly reduces inflammation, whereas unwanted immune-suppressive side effects are reduced
  • New drug target in Alzheimer’s disease

    B74174

    New drug target in Alzheimer’s disease

    • Aη-α as a new drug target and / or diagnostic marker for Alzheimer’s disease
    • Inhibition of β-secretase leads to accumulation of Aη-α
    • Antibodies to detect η-secretase pathway peptides are available

44 of 90 Tech Offers

Interested? Get in touch!

Contact a specific team member for individual topics via the Team section or simply use our contact form. You can also click on the button and drop us a line.